Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 5, 2012, Pages 513-519

  Ford, Alexander C ^a,b   Khan, Khurram J ^c   Sandborn, William J ^d   Hanauer, Stephen B ^e   Moayyedi, Paul ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Clinical Trial; Colon; Drug Treatment; Inflammation

Indexed keywords

MESALAZINE; PLACEBO;

COMPARATIVE STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; REVIEW; RISK FACTOR; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859857709     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.10.043     Document Type: Review

References (33)

1. Cosnes J., Gower-Rousseau C., Seksik P., et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140:1785-1794.
2. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007, 5:1424-1429.
3. Loftus E.V., Silverstein M.D., Sandborn W.J., et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000, 46:336-343.
4. Loftus C.G., Loftus E.V., Harmsen W.S., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13:254-261.
5. Talley N.J., Abreu M.T., Achkar J.-P., et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011, 106(Suppl 1s):S2-S25.
6. Ford A.C., Bernstein C.N., Khan K.J., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:590-599.
7. Ford A.C., Achkar J.-P., Khan K.J., et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:601-616.
8. Marshall J.K., Thabane M., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, 1. CD004115.
9. Sutherland L., MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 2. CD000543.
10. Sutherland L., MacDonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 2. CD000544.
11. Travis S.P., Stange E.F., Lémann M., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008, 2:24-62.
12. Mowat C., Cole A., Windsor A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607.
13. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523. Practice Parameters Committee of the American College of Gastroenterology.
14. Regueiro M., Loftus E.V., Steinhart A.H., et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12:979-994.
15. Cohen R.D., Woseth D.M., Thisted R.A., et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000, 95:1263-1276.
16. Marshall J.K., Irvine E.J., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (protocol). Cochrane Database Syst Rev 2003, 1. CD004118.
17. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions: version 5.0.0 Accessed August 25, 2011. http://www.cochrane-handbook.org.
18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. Egger M., Davey-Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
21. Sterne J.A., Sutton A.J., Ioannidis J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002.
22. D'Albasio G., Pacini F., Camarri E., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997, 92:1143-1147.
23. Hanauer S., Good L.I., Goodman M.W., et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance in ulcerative colitis. Am J Gastroenterol 2000, 95:1749-1754.
24. Biddle W.L., Greenberger N.J., Swan J.T., et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988, 94:1075-1079.
25. D'Arienzo A., Panarese A., D'Armiento F.P., et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990, 85:1079-1082.
26. D'Albasio G., Paoluzi P., Campieri M., et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. Am J Gastroenterol 1998, 93:799-803.
27. Marteau P., Crand J., Foucault M., et al. Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998, 42:195-199.
28. Miner P., Daly R., Nester T., et al. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 1994, 106(Suppl 2):A736.
29. Andreoli A., Spinella S., Levenstein S., et al. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Ital J Gastroenterol 1994, 26:121-125.
30. D'Albasio G., Trallori G., Ghetti A., et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990, 33:394-397.
31. Mantzaris G.J., Hatzis A., Petraki K., et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994, 37:58-62.
32. Ford A.C., Khan K.J., Achkar J.-P., et al. Efficacy of oral versus topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011 Nov 22, [Epub ahead of print].
33. Moody G.A., Eaden J.A., Helyes Z., et al. Oral or rectal administration of drugs in IBD?. Aliment Pharmacol Ther 1997, 11:999-1000.